PK Bridging Study Application via Ethnic Sensitivity Analysis
For modified-release formulations, a PopPK model is built to determine optimal dosing regimens for Chinese subjects. Combined with ethnic sensitivity analysis, we support PK bridging study application and subsequent NDA submission.
B²O Pharma is an innovative pharmaceutical R&D enterprise focusing on AI-driven clinical pharmacology and quantitative pharmacology, dedicated to advancing model-informed drug development.